Clinical and molecular characteristics of CLL patients in this study
| Patient . | Age, y . | Sex . | Rai stage . | IGHV mutation . | Methylation . | Immunophenotype . | 2H2O . | Cytogenetic abnormalities, % cells . | Outcome . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % Diff . | Status . | 5 CpGs . | ZAP70, % cells . | CD38, % cells . | BR, %/d . | Δ17p23 . | Δ13q14 . | Tri12 . | Δ11q22 . | Trt . | TTFT, mo . | ||||
| P40489 | 51 | M | 0 | 7.0 | M-CLL | m-CLL | 3.92 | 1.1 | 0.14 | 0 | 0 | 0 | 0 | — | 22 |
| CLL606 | 49 | M | 0 | 6.2 | M-CLL | m-CLL | 1.7 | 0.4 | 0.15 | 0 | 96 | 0 | 0 | — | 76 |
| CLL1026 | 44 | F | 0 | 10.3 | M-CLL | m-CLL | 1.4 | 2.1 | 0.16 | 0 | 0 | 0 | 0 | — | 45 |
| CLL276 | 68 | M | 1 | 5.3 | M-CLL | m-CLL | 4.3 | 6.6 | 0.19 | ND | ND | ND | ND | BR | 23 |
| CLL1127 | 60 | M | 0 | 7.6 | M-CLL | m-CLL | 0.42 | 3.4 | 0.21 | 0 | 84 | 0 | 0 | — | 60 |
| CLL373 | 52 | F | 1 | 12.4 | M-CLL | m-CLL | 16.8 | 1.2 | 0.28 | ND | ND | ND | ND | — | 58 |
| CLL584 | 53 | M | 0 | 6.6 | M-CLL | m-CLL | 1 | 1.2 | 0.28 | 0 | 0 | 0 | 0 | — | 75 |
| P40323 | 63 | F | 0 | 9.8 | M-CLL | m-CLL | 7.34 | 1.7 | 0.29 | 2 | 71.5 | 0 | 0 | — | 39 |
| CLL638 | 53 | M | 0 | 3.2 | M-CLL | n-CLL | 63.7 | 0.8 | 0.31 | 0 | 0 | 0 | 0 | — | 58 |
| P40344 | 55 | M | 1 | 6.6 | M-CLL | m-CLL | 19 | 9.1 | 0.35 | 0 | 0 | 0 | 0 | O | 31 |
| CLL331 | 77 | M | 1 | 3.9 | M-CLL | m-CLL | 73.6 | 11 | 0.36 | ND | ND | ND | ND | — | 69 |
| CLL1039 | 51 | F | 0 | 3.9 | M-CLL | m-CLL | 1.7 | 0.9 | 0.37 | 0 | 88 | 0 | 0 | FCR ×4 | 9 |
| CLL499 | 65 | M | 2 | 6.0 | M-CLL | m-CLL | 0.9 | 3.3 | 0.58 | ND | ND | ND | ND | FR ×4 | 9 |
| CLL650 | 53 | M | 1 | 0.0 | U-CLL | i-CLL | 40.2 | 94.9 | 0.20 | 0 | 0 | 0 | 69.5 | FR ×2 | 10 |
| CLL609 | 61 | M | 1 | 0.3 | U-CLL | n-CLL | 51.3 | 16.8 | 0.33 | 0 | 11.5 | 0 | 0 | FCR ×6 | 28 |
| CLL625 | 53 | M | 2 | 0.0 | U-CLL | n-CLL | 32.3 | 41.7 | 0.39 | 0 | 0 | 0 | 100 | FR | 6 |
| CLL452 | 51 | M | 1 | 0.0 | U-CLL | n-CLL | 43.8 | 20.5 | 0.48 | ND | ND | ND | ND | FR | 16 |
| CLL934 | 57 | F | 1 | 0.0 | U-CLL | n-CLL | 61.1 | 4.5 | 0.56 | 0 | 0 | 53.5 | 0 | FR ×5 | 7 |
| CLL569 | 55 | M | 2 | 0.7 | U-CLL | n-CLL | 45.8 | 86.5 | 0.81 | 0 | 0 | 0 | 0 | FCR | 16 |
| CLL493 | 56 | M | 2 | 0.0 | U-CLL | n-CLL | 93.8 | 98 | 0.96 | ND | ND | ND | ND | RCD ×3 | 19 |
| CLL753 | 69 | M | 1 | 0.0 | U-CLL | n-CLL | 73.5 | 76.3 | 1.03 | ND | ND | ND | ND | FCR ×4 | 2 |
| Patient . | Age, y . | Sex . | Rai stage . | IGHV mutation . | Methylation . | Immunophenotype . | 2H2O . | Cytogenetic abnormalities, % cells . | Outcome . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % Diff . | Status . | 5 CpGs . | ZAP70, % cells . | CD38, % cells . | BR, %/d . | Δ17p23 . | Δ13q14 . | Tri12 . | Δ11q22 . | Trt . | TTFT, mo . | ||||
| P40489 | 51 | M | 0 | 7.0 | M-CLL | m-CLL | 3.92 | 1.1 | 0.14 | 0 | 0 | 0 | 0 | — | 22 |
| CLL606 | 49 | M | 0 | 6.2 | M-CLL | m-CLL | 1.7 | 0.4 | 0.15 | 0 | 96 | 0 | 0 | — | 76 |
| CLL1026 | 44 | F | 0 | 10.3 | M-CLL | m-CLL | 1.4 | 2.1 | 0.16 | 0 | 0 | 0 | 0 | — | 45 |
| CLL276 | 68 | M | 1 | 5.3 | M-CLL | m-CLL | 4.3 | 6.6 | 0.19 | ND | ND | ND | ND | BR | 23 |
| CLL1127 | 60 | M | 0 | 7.6 | M-CLL | m-CLL | 0.42 | 3.4 | 0.21 | 0 | 84 | 0 | 0 | — | 60 |
| CLL373 | 52 | F | 1 | 12.4 | M-CLL | m-CLL | 16.8 | 1.2 | 0.28 | ND | ND | ND | ND | — | 58 |
| CLL584 | 53 | M | 0 | 6.6 | M-CLL | m-CLL | 1 | 1.2 | 0.28 | 0 | 0 | 0 | 0 | — | 75 |
| P40323 | 63 | F | 0 | 9.8 | M-CLL | m-CLL | 7.34 | 1.7 | 0.29 | 2 | 71.5 | 0 | 0 | — | 39 |
| CLL638 | 53 | M | 0 | 3.2 | M-CLL | n-CLL | 63.7 | 0.8 | 0.31 | 0 | 0 | 0 | 0 | — | 58 |
| P40344 | 55 | M | 1 | 6.6 | M-CLL | m-CLL | 19 | 9.1 | 0.35 | 0 | 0 | 0 | 0 | O | 31 |
| CLL331 | 77 | M | 1 | 3.9 | M-CLL | m-CLL | 73.6 | 11 | 0.36 | ND | ND | ND | ND | — | 69 |
| CLL1039 | 51 | F | 0 | 3.9 | M-CLL | m-CLL | 1.7 | 0.9 | 0.37 | 0 | 88 | 0 | 0 | FCR ×4 | 9 |
| CLL499 | 65 | M | 2 | 6.0 | M-CLL | m-CLL | 0.9 | 3.3 | 0.58 | ND | ND | ND | ND | FR ×4 | 9 |
| CLL650 | 53 | M | 1 | 0.0 | U-CLL | i-CLL | 40.2 | 94.9 | 0.20 | 0 | 0 | 0 | 69.5 | FR ×2 | 10 |
| CLL609 | 61 | M | 1 | 0.3 | U-CLL | n-CLL | 51.3 | 16.8 | 0.33 | 0 | 11.5 | 0 | 0 | FCR ×6 | 28 |
| CLL625 | 53 | M | 2 | 0.0 | U-CLL | n-CLL | 32.3 | 41.7 | 0.39 | 0 | 0 | 0 | 100 | FR | 6 |
| CLL452 | 51 | M | 1 | 0.0 | U-CLL | n-CLL | 43.8 | 20.5 | 0.48 | ND | ND | ND | ND | FR | 16 |
| CLL934 | 57 | F | 1 | 0.0 | U-CLL | n-CLL | 61.1 | 4.5 | 0.56 | 0 | 0 | 53.5 | 0 | FR ×5 | 7 |
| CLL569 | 55 | M | 2 | 0.7 | U-CLL | n-CLL | 45.8 | 86.5 | 0.81 | 0 | 0 | 0 | 0 | FCR | 16 |
| CLL493 | 56 | M | 2 | 0.0 | U-CLL | n-CLL | 93.8 | 98 | 0.96 | ND | ND | ND | ND | RCD ×3 | 19 |
| CLL753 | 69 | M | 1 | 0.0 | U-CLL | n-CLL | 73.5 | 76.3 | 1.03 | ND | ND | ND | ND | FCR ×4 | 2 |
BR, bendamustine, rituximab; F, female; FCR, fludarabine, cyclophosphamide, rituximab; FR, fludarabine, rituximab; i-CLL, intermediate CLL; M, male; m-CLL, memory B-cell–like CLL; M-CLL, IGHV-mutated CLL; n-CLL, naive-cell–like CLL; ND, not determined; O, ofatumumab; RCD, rituximab, cyclophosphamide, dexamethasone; Trt, treatment required within a 7-year follow-up period (numbers indicate cycles of treatment, if received); TTFT, time to first treatment (or last follow-up if untreated) from the start time of the heavy water protocol; U-CLL, IGHV-unmutated CLL; % Diff, percent deviation to germline in IGHV sequence (<2% is considered unmutated).